Good afternoon and thank you for joining us today to discuss OptimizeRx Corporation's First Quarter ended March 31, 2020. With us today are the company's Chief Executive Officer, William Febbo; the President, Miriam Paramore; the Chief Financial Officer, Doug Baker; and Chief Commercial Officer, Stephen Silvestro. Following management's remarks today we'll open the call to questions. Then before we conclude today's call I'll provide some important cautions regarding the forward-looking statements made by management during the call. I'd like to remind everyone that today's call is being recorded. And will be made available for telephone replay via instructions in today's press release in the Investors section of the company's website. Now I would like to turn the call over to OptimizeRx CEO, William Febbo. Please go ahead.

Thank you operator and thank you and good afternoon everyone. Thanks for joining us on this call today especially during these difficult times globally. I'd like to start by highlighting the bravery and sheer strength healthcare providers brought to our respective communities. Prior to the pandemic the day-to-day was already challenging. Layering on the volume of those needing care requires a level of commitment that is truly spectacular and hard for us not on the front line to fully appreciate. They are heroes in these times. We all thank you. I believe this period of history to be one for future generations will study and judge from our successes and failures they will learn what to do not to do who to count on what's considered exemplary leadership and bravery and what tools are needed to preserve life business and cultural continuity. As been highlighted by many most countries have done a terrible job preparing for a pandemic. So it's on all of us to be safe and considerate of others as we reenter the world. And we must learn and improve and move forward differently so we can avoid such a dramatic disruption in the future. That being said I'm an optimist. So I tend to look for the positives in such times of trouble while being respectful for those still fighting a very real fight against this pandemic. At OptimizeRx we have tried to do our part to help providers and patients. In late February we began using our point-of-care network to stream free real-time CDC alerts for healthcare providers and use our mobile technology platform to deliver free SMS updates to anyone who wanted to sign up for them. In late February, we began using our point-of-care network to stream free CDC filings and it was very helpful for all those who've signed up. We also gathered thought leaders from several major companies to discuss the impact of COVID-19 on a range of critical areas from continued care to company policies to the rapidly evolving telehealth industry and how we manage our business in times of quarantine. I want to say I'm proud of our team for pulling all this together so quickly and I've been impressed with our partners and other executives for sharing their wisdom so openly without concern for a commercial benefit. Today, we're going to run the call slightly differently. While I have my full executive team calling in with me Doug will give a quick overview of the financials and then I'll give opening comments and then we'll open it up to questions to the analysts. Now before we dive into the operational details from the first quarter Doug take it away.

Thanks Will and good afternoon everyone. Earlier today we issued a press release with the results of our first quarter that ended March 31. The copy is available for viewing and may be downloaded from the Investor Relations section of our website. We will be filing our 10-Q later this week as well. Our revenue for the quarter was a record $7.6 million up 46% compared to a year ago. Gross margin was $4.3 million up 20% versus a year ago. Our gross margin percentage declined to 57.3% in the quarter which was a result of an unusually favorable product mix in the first quarter of 2019 and a heavier mix of financial messaging this year. We still expect to achieve a minimum gross margin of 60% for the calendar year and are targeting a gross margin of 63%. Our operating expenses increased to $6.6 million in the first quarter 2020. The increase reflects the investment that we've made in our team and growth initiatives and you can see the positive impact of this investment in our results for this quarter. Our investment in our commercial organization led to a 46% increase in revenue a shift towards enterprise contracts and a decreased sales cycle. Our investment in our marketing and product teams gave us the ability to be nimble and quickly respond to some of the operational items Will is discussing on the call. Adjusted EBITDA which we report as a non-GAAP financial measure was a loss of $830000 in the first quarter as a result of these growth initiatives. Our balance sheet remains strong. Cash and cash equivalents total $15.2 million down from $18.9 million at year-end. This decrease resulted from the increased working capital required to fund growth, including payments to our partners and increased receivables from our customers. We expect these to level out over the remainder of the year. And we expect to generate positive cash flow from operations for the full year. We have continued to operate debt-free and do not anticipate needing to raise additional capital, over the foreseeable future, for operating purposes or to fund our growth plans. This wraps up our financial results. I'd like to turn the call back over to Will.

Thanks Doug. In talking with investors, clients and my team over the last six weeks, there seem to be two recurring questions. What steps have we taken to lessen the impact of COVID-19 on business continuity with regard to the team, clients, partners and our balance sheet? And does OptimizeRx have a long-term strategic competitive advantage, which will be reflected in our results and shareholder value? While I'll start with a caution that we are all on new ground, when it comes to the level of disruption due to COVID-19. At OptimizeRx, we feel fortunate to be so well situated in the market and able to affect digital communication among providers, patients and the health care industry. In terms of business continuity our teams normally operate in a semi virtual basis, distributed work environment. So we saw practically no disruption in operations, although early on we decided to stop travel and work from home as a precaution for our team, and families. We were already big users of video conferencing. So we were able to service our clients and partners, as we usually do and without much difficulty. Given our greater use of video communication, I am actually seeing more and many more of our team-mates on a daily basis, which has been a great thing. We're also fully cloud-based with AWS, so our technology and security remains solid through these times. And can handle any increase in activity. My hat is off to everyone in dealing with this change. The entire team has really stepped up. While late February and early March were very challenging for our clients and our partners, we saw very little disruption in decision-making and interaction, albeit virtual. We are thankful we have many, very well-established relationships with our clients. And while none of us want to see this continued disruption, we have seen a dramatic increase in activity, and need for our solutions among our client base. To-date we have not seen any pharma programs eliminated or decreased. But I'm sure the executives are all watching events unfold. And we are ready to adjust if need be. There is no question that office visits are down markedly from late February. Some have said between 25% and 60%, depending upon specialty. We expect that to hold true through the end of June and possibly later again in the year. With regard to impact on our business, the providers are still using their EHRs from home. And it is also important to remember that we focus on, essential medications, not elective. With regard to the impact on our business, the providers are still using their EHRs at home. And it's just, key that we stay with them. We have not seen a drop in our branded e-prescriptions. Of course, we're thrilled by our 40s percent -- 46% increase in year-over-year revenue growth. But perhaps more importantly, we have seen our close rate increase to above 50% and our sales cycle decreased from 90 to 30 days lately. We continue to receive positive responses to proposals for enterprise-level engagements, which when viewed together, have an average annualized contract value of about $3.6 million. We also feel we have some strong tailwinds at our back in terms of our client base. Most of our clients have decided not to hold off on new launches. This is due to the complexities and costs around preparation, and as part of the overall strategy designed to prevent any substantial disruption. Medical conferences, medical liaisons and live advisory boards have all been disrupted. So we expect this to drive an increase in demand for digital communication that delivers mission-critical information. The FDA is also committed to accelerating approvals of new medications and indications, so many new novel therapies will be coming to market over the coming months and years. This should help provide a healthy pipeline of new opportunities in the future. While many of our channel partners already had telehealth solutions, the adoption has been relatively low to-date. The recent increase in demand for these types of services has been fantastic for all involved. For us, it is implied benefit of our channel partners and the providers increasing their attention on those essential tools in order to care for patients. Telehealth is an obvious solution to add. But affordability and adherence our core solutions, have also moved up on the priority list. As a result, the discussions that we're progressing normally with new potential partners have all been advanced around enabling affordability and adherence tools to deliver at point of care. We expect this to have a lasting positive impact on our ability to grow and continue to build strong value within our network. Internally, we have accelerated several launches of new solutions that not only solve problems for our clients but also allow us to further showcase to the market the power of our innovation lab and technology we've acquired. We recently highlighted our TelaRep solution as an offering that can help providers connect with our clients', medical liaisons or sales representatives when they have a specific question. We expect this to be additive this year to a degree and going forward becoming a terrific addition to our enterprise solutions for specialty medications. We also highlighted a few clients recently in a press release that use our virtual care or telehealth solution, which we acquired with RMDY in Q4 of 2019. Given the global adoption of these virtual care methods of interaction and general feeling that the markets will not revert to previous adoption levels post COVID 2019, we expect this to help us scale the business for the years to come. We also view our telehealth solution as a very effective tool for our massive patient engagement group, which will have more to share in the coming quarters. As we highlighted in the recent press release, we were honored to help O2, a client maintain care for its cardiac patients, when their rehab centers were shut down due to COVID-19. I believe the market will see our entry with these new solutions as a very effective tool. Relative to our core messaging solution and COVID-19, we are seeing an increase in demand for financial messaging from our client base. Given the unemployment levels cost has again surfaced as a major problem for patients and we expect these trends to continue. As reflected in the slight drop in gross margin in Q1, we will bring our cost of sales up a bit, as these products are largely connected to providers through legacy contracts and thus a higher revenue share. However, we remain confident that our gross margin will improve and level off at the 58% to 62% range by the year-end with a positive impact from enterprise deals flowing through the P&L and continued growth in patient engagement. We feel confident in this outlook as enterprise deals and patient engagement and forward revenue continue to grow. And actually, we are thrilled with this as we began our shift to this model less than a year ago. Our balance sheet, as Doug said, remains strong debt-free and we're very diligently managing expenses to assure our flexibility in this market. And to be sure, at this time we don't see any need to raise capital for operational purposes. So does OptimizeRx have a long-term sustainable competitive advantage? We think so. We are a digital health platform that brings together a very fragmented market of healthcare information technology, connecting patients and providers within the healthcare. We have the ability to connect all stakeholders in healthcare, in a way that fits into their daily lives and touches on the pain points we have all experienced, which could include awareness, affordability and adherence of our medication to live a healthy life. We've built a meaningful position reach over the years with some measure of exclusivity by integrating our platforms into leading EHRs and e-prescribing systems. Today, we reached 60% of the ambulatory market and that is where most prescribing happens. We have also become deeply entrenched in our client base. We work with the top 20 pharmaceutical companies and more than 60 other clients, all of which have multiple siloed businesses in need of our services. The trust we have gained from our clients in supporting a continued shift to SaaS-based enterprise-level recurring revenue model. And we sit squarely in one of the fastest-growing segments in health technology that is point-of-care communications, where there's a tremendous client demand for greater connectivity that is effective, transparent and measurable, all of which we do. Our addressable market is much bigger than it was even two months ago with the recent explosion of telehealth and our connection to it. And you couple that with patient engagement and we're sitting in a multi multibillion-dollar addressable market. Given the moat that this builds around us, my excitement for the future is at its highest since I joined OptimizeRx in 2016. We live in a digital age and we strive to be the best digital platform for everyone we work with. Today, we have a scalable secure technology to support and protect our growth. So when the doctor and the patient are working together to solve issues, we can be there timely – when it's timely and appropriate. Above all, and as I said, each time this is very important to me personally, we're fostering a great work culture and environment continues to be our top priority, which as any business leader knows or savvy investor, it's what makes a great company. We expect the key benefit of the focus to yield on more predictable recurring revenue, deeper relationships with our clients and ultimately the ability to innovate with our partners in a way to keep us ahead of the changes and opportunities in the market. Now with that I'd like to open up to your questions. Operator?

Thank you, Sir [Operator Instructions] And we'll take our first question from Andrew D'Silva with B. Riley FBR. Please go ahead. Andrew D'Silva: Yeah. Thank you. Good afternoon. I'm glad to hear everyone sounds healthy. And again thanks for taking my questions. Just to start maybe just a little bit of context on how you're seeing enterprise solutions develop and are you seeing the seasonality of RFPs change specifically as it relates to more activity currently than is traditionally experienced perhaps at this point in the year?

Hey, Andy, yes. I'll start and then I'll hand it over to Steve. So traditionally, this is the year where we, sort of, stopped talking about pipeline because we're closing business and executing against what was as you know a record pipeline to Q4 and Q1. But we -- given everything going on we're actually seeing a pickup in that actual pipeline as well as a higher close rate. We attribute that mostly just to the need to communicate digitally with so much else being disrupted in terms of the medical conferences, sales, medical liaisons and sales representatives and just travel in general. But Steve, let me hand it over to you.

Yes. Thanks, Will. Hey, Andy. I think in addition to, sort of, the market-driven forces that are going on out there you know that we onboarded several key talents at the end of last year commercially and those are now fully ramped and they're starting to produce as well. So we're, sort of, moving past that general RFP piece as Will says and we're driving more demand through that team in addition to the market-driven demand. Andrew D'Silva: Okay. Great color. It's good to hear and see that progress. And then just next question just curious if you could just discuss how the sales team is performing as your headcount grows. And just a little additional color on deal cycles, sales outreach and how you're seeing expanding into additional brands with existing clients are you seeing traction there?

Steve, do you want to take that one?

Yes. I'm happy to. So a couple of things that we've really been focused on Andy just managing the commercial organization are really the three levers of volume, value and velocity. So increasing the volume of deals in the pipeline and those that we can execute on. The deal value, obviously, we've talked about ACV now publicly. You know that we had a significant growth in pipeline value and deal size. We saw that same value transfer over to executed deals which is part of our growth story. And then, of course, the velocity and we've seen the deals now close in 30 days. So we're focusing on those three levers of execution and the team is being managed extremely tightly and doing an excellent job of really focusing in and executing. The land and expand pieces have proven really successful as well as we've -- as you heard Will say in the top 20 clients we're very well-penetrated, but we're penetrated with maybe one or two brands. We've been able to mushroom that out and expand very well as clients have been very satisfied with existing solutions. They've provided internal referrals and we've capitalized on those internal referrals and being able to grow the business in that way as well. So I think that will continue on as we continue to prove ourselves to our clients and do a great job and deliver value to the market. Andrew D'Silva: And you're seeing that largely because of the transition towards enterprise solutions? Or is it just a couple other dynamics going on at the same time?

It's, sort of, both. We're seeing really good -- really positive feedback from the enterprise solutions. So we had talked about last year in our fourth quarter call about the compounding effects of bringing multiple solutions into the platform and utilizing those to drive better adherence and to produce better outcomes. We're seeing that in the data, which is really encouraging for our customers. So I think that's part of it. I also think the market forces of there need to be able to communicate digitally at the point of care when we've seen basically a 100% reduction in sales force out on the street is just -- is fueling that. So it's a combination. One thing that I've also seen or that we're also seeing Andy, as a result of that is just, clients looking for more opportunities to communicate digitally at the point-of-care even outside of what they're currently familiar with. And so, the launch of TelaRep, again, is really us capitalizing on an opportunity that we have to deliver more value to our customers at the point-of-care and enable those HCPs to get the information that they need to treat their patients. Andrew D'Silva: Okay, okay. Got it. That's very good color. And so, last question for me and I'm sorry, you may have touched on this, but my connection was a little choppy. But just, as it relates to taking advantage of the telehealth tailwind created by COVID-19, could you just talk about how you're expanding the reach RMDY previously had, now that it's integrating into the OPRX broader platform?

Miriam, you want to talk to that? You may be on mute.

Sure. Yes. Tend to come off of mute. Yes. Sorry about that. Sorry about that. I'm here. Hi, Andy. Yes. Andy, we have really a virtual care delivery mechanism in RMDY. And when we acquired it and we saw all of the different things that we could do with the platform, was already in use for a variety of use cases. So those include things that are -- the care delivery of cardiac rehabilitation as we mentioned before, mental health services as we talked about before. And so, our vision on incorporating it with the larger OPRX portfolio is simply that it's digital reach for the sort of virtual care larger umbrella, which includes point-of-care communication for the purposes of the medication affordability and adherence historically in our network, Andy, but now includes these virtual care tools. So you have patients and providers on one side or each side of a conversation that you may have health coaches and others on the other. So each of these are now -- this is a new virtual point-of-care that's outside the EHR and it's where we know we can support the demand for digital communication from our historical industry stakeholders in life sciences. So that's how we're bringing the two together. I hope that's helpful. Andrew D'Silva: Actually, that's very helpful and really quite interesting actually. Well, that’s it for me. Thank you very much. Please stay safe and healthy and good luck going forward this year.

Thanks, Andy. You too.

And our next question is with Richard Baldry with Roth Capital. Please go ahead.

Thanks. Can you maybe talk and add a little color around the enterprise deals sort of as it sits in new area? How fast do you think some of those can launch and get up to sort of full stride? Because I assume most of these are with existing customers expanding. Is that relatively quick? Or is there any reason to think that those will be slower as they kind of move into broader brands or broader product sets with the company?

Steve, do you want to grab that?

Yes. Happy to. Hey, Rich. Yes. I mean the enterprise deals are basically on a 30 to 45-day launch track right now at this point. Some of the more complex ones maybe 60 days before they launch and go live. But what we're seeing is a tremendous push on the client side to get them live. So the things that would have been larger hurdles previously like elongated MLR processes, just delays on getting content or delays on getting creative from agency partners. Those have all been accelerated because folks are trying to find quick ways to get communication out the door and to the HCPs. So we're being enabled a little bit by the current environment, Rich, if that makes sense.

Sure. In some prior years we've seen the seasonal challenges when maybe macroeconomic conditions offered a headwind to end customers for whatever reason. Obviously, COVID has its own end market challenges in pharma. But your tone is really not signaling any change to their marketing spend at least with yourselves. Maybe, I guess, obviously, the digital communications got some defensibility, but I'm still surprised how clean you're coming through this. Can you maybe talk about some of the prioritization discussions you've had with your pharma companies, sort of why you think this time around you're so much more defensible than we've seen in the past?

Yes. I'll start and then Steve you fill in. So we have to be a little careful, because obviously our clients are sharing a lot of stuff with us. They're large public companies and don't even like that we're public. So -- then have to talk about this. So, the reality is though everything that's happening now has been in the works for 12 to 18 months in terms of launch activities and support activities. And as everyone knows the marketing spend in pharma is huge. If you add conferences and medical liaisons and ad boards and all the things they do. So everyone was coming into early 2020 with that just prep to go. And obviously that was completely disrupted. So you wouldn't want to put the brakes on there, because there's still -- so much had gone into getting a medication ready to be sold. And so when you take that content material in time, you're not going to slow it down. You're going to try to get it to move. And so, we have not seen that pull back. We've seen -- I'm sure they're being cautious with certain brands. But again, as I mentioned in my prepared remarks, we're focused on really the essential medications not elective. I think our elective is probably getting more of a pullback. I think also sort of in personal marketing things that are digital probably getting a pull back, because we're not sure people are seeing them. Remember, we are at point of care doctors with the patient and we only deliver what's relevant to the two when they're together. They're never hit with anything that is not relevant. So I would just put all that into one. But Steve, why don't you fill it out?

I think you summed it up really nicely. I think the one additional comment that I would say is that, the medications that are being delivered that we're supporting are as Will says essential medications. And that really is a critical fact. And I think when we look at the script volumes over time we've seen dips in, what I would say, our lifestyle type medications, which generally speaking we're not supporting as much. But the critical medications if you could think about type two diabetics Rich or you think about human cancer patients, those people will not be able to come off therapy for long periods of time without significant harm being done number one. Number two, rehospitalization rates will radically increase, if we -- as a health system pause treatment of those patients for a long period of time. And I think everyone is cognizant of that. So prioritization is happening along those lines.

And sort of trying to get into more changes in behaviors that this might have driven, So are there any metrics around sort of usage by docs when they're at home with the EHR sort of like a penetration or adoption rates changing that you can see? Or is it too early maybe for that? And then, maybe on the prospect side also any increased activity from new local potential customers outside of the top 20 plus 60 that you were surprised by that might have understood the value proposition much better in a post-COVID world.

Miriam, you want to take that question?

Yes. Yeah. Okay. So, what we're seeing is consistent utilization of the EHRs, because that's -- it's -- you can dial into it from anywhere. Doctors are very used to accessing the electronic health record via their home computer or even their mobile device or their iPad. So, all of that is line one communication and part of their daily lives. So they're on it all the time. What's happened is, the extraordinary ramp of the use of the Sidecar telehealth tool that in those cases is not inside the HER, it's in addition to the EHR. And so -- and what that really means -- Will was talking about telehealth earlier and we just talked about virtual care. Virtual care is a much broader way to think about it that telehealth is kind of it does work that people are saying. What the doctors are doing right now is using the tools for specifically for telemedicine purposes or for e-visit purposes. And because the reimbursement to physicians has been expanded specifically to 80 billable codes and so forth, they can have confidence that they can bill in this less restrictions around the use of that technology than they used to be in terms of regulatory restrictions and reimbursement restrictions. So, that is happening typically outside the HER, but then it also has to be coupled with the EHR because of the scheduling and the sort of master chart in the actual EHR. So, we're not seeing any slowdown there but we're seeing in addition to. And then you're -- I think you're going to see that continue going forward.

And Steve do you want to take that second one part of the question?

Yes. Happy to. Rich to answer your question I mean we're seeing significant activity outside of the top 20 even small to mid-pharma businesses are coming to the table with digital questions and a willingness and sort of funding to engage several of the larger deals that we've done have been mid pharma deals, which has been excellent. And we'll -- I think we will continue to see that same trajectory for those tiers of customers coming to the table. It's been really encouraging.

And lastly just looking into the financial model. The -- do we expect to see any change to your sort of seasonal revenue pattern from what you would consider a norm given the change in the -- COVID's brought to the contracting and sort of pipelines? And then sort of same question below the line on the spending side because of the increased pipelines and faster close rates do you feel like you might come into the year knowing what you thought you'd need to hire maybe that needs to accelerate somewhat just so we get a feel for the top and bottom-line patterns for the year? Thanks.

Yes. Sure. So, as I said in my comments it's really hard to know for sure because we all look at this on a monthly basis. Most big public companies are not giving -- or pulling guidance. So, we don't want to -- we want to be humble but we are in the right place at the right time for our clients and for providers and patients. So, we're not seeing a disruption to the seasonality. If we see one partially it would be in Q2 just because of the sort of late March -- late February March hit. But again we feel pretty confident we're going to work through that. And again if anything substantial changes we would update our investors. But right now we're -- as you're hearing we're feeling very confident that we can sort of stay to a similar seasonality. Relative to hiring so we didn't actually have a lot of hiring into this year. As we said we did a lot of investing last year just not just through acquisition but also building the team out. And they are really hitting it hard and obviously, when this started, we kind of put a hold on hiring because we didn't know. But again in our model it is very leverageable. We have a team that can execute as long as we're doing what we say which is digitizing content and distributing it it's really one of those that you don't need to add a lot of people to scale further. So, as of now we feel like we have the team to continue on to a really nice growth record this year and we'll keep everyone updated on anything if it changes. But right now we're feeling very good about it.

Great. Congrats on a good start to the year on a tough backdrop.

Thank you.

And our next question Ryan Daniels with William Blair. Please go ahead.

Yes guys, congrats on a strong quarter. Thanks for taking the question. One just a housekeeping one. My phone is going in and out. Can you go back over the close rate details? What it was kind of prior to entering the quarter then what you're seeing at present?

Sure. Steve you want to take that? He might be on mute. I'll start. So, generally, we gave a range of 30% to 50% late in the year last year and talked about it again when we reported Q4. We're seeing it above 50%. I think that's -- my hats off to the team that really I think we had a more curated pipeline meaning just a lot more substance behind it. That generally leads to a higher conversion rate. We also know what are fees to stay away from when the market's just sort of shopping for pricing. And also we're just seeing a faster close rate. So, generally it was a 90-day close rate that's shifted down to 30 days, which is tremendous in this business. And Steve if you want to add to it it's really -- so a really positive thing for us as a team.

Yes. That's great Will. Thanks. Sorry I was on mute. 2018 was 35%. Like Will said last year we eked up to 39% and now we're at 52%. And the team has just done a fabulous job around there focusing on the right deals for the business and also increasing as Will said the velocity of closing those deals. And it's just -- it's created a tremendous output from the group. So, very proud of what the team has done.

I don't know, if there's a way to look at this or if you want to provide this much detail, but is the close rate higher because of your sophistication on sales and investments and your broader product offering? Meaning was the close rate factored in January and February? Or did it really accelerate in March as these conferences got canceled and as providers had to – or manufacturers had to turn towards more digital channels to help with product promotion and product launches? So if COVID didn't take place and you trended the same let's say as January and February would it still be above 50%? Or is COVID really helping?

Steve?

Yes. I don't think we can break it out by month Ryan. But my sense is that, it's probably a blend and the team has done an incredible job of focusing on execution, and we're already off to a great start in January and February, before COVID really broke out. We did see a good uptick in March as well. But I think that the close rate really is due to focus on execution. I think what we see that is more COVID correlated with be the sales cycle. So instead of 120 days or even 80 days, which was sort of last year's average sales cycle we're seeing right around a little north of 30 days as Will said. And I do think that's correlated to the market dynamics of customers really being anxious to get out and get communication out there and launch programs, which is excellent. And we're doing our best to try to help them in an efficient and meaningful way, so that they can get their programs live and help the HCPs they're supporting.

Sure. And final question, I'll hop off. Is this kind of elevated digital marketing, if you will from a brand manager-specific pharmaceutical brand to an entire product category manager? Or even to a C-suite level as they see the need to kind of get their drugs out there that they've invested a lot of R&D in? And as the FDA accelerates potential drug approvals are going to need a way to get to market? Is this becoming a C-level issue for the first time for your organization and potentially an inflection point because of that?

You want me to hit that Will? Yeah. Okay. Yeah. I mean, we've seen over the last 24 months Ryan a pivot inside of most pharmaceutical organizations where the focus on digital outreach has become more provident. Several large manufacturers have announced Chief Digital Officers, which you would have seen in the news. That seat is now a more prominent one to your point at the table as they are really relying on that person to orient the business around communication outwardly to HCPs almost entirely. Pharmaceutical brands right now have pretty much pulled all of their sales reps off of the floor. And so they're finding ways to enable those sales reps digitally and virtually. But again, it all comes down to the core digital strategy of how do you do that. And how does it become a pull strategy as opposed to a push strategy. No HCP wants to be bombarded with inappropriate information at incorrect times. But universally all of the market research is being done out there right now, and there is lots of it. Demonstrates that HCPs want to hear from manufacturers and they want correct information that's timely and reliable and appropriate for their patient. So net-net, it's becoming a much more prominent role within these organizations.

Okay. Thank you for all the color. And stay safe guys, Thanks.

Thanks, Ryan.

And our next question comes from Eric Martinuzzi with Lake Street. Please go ahead.

Thanks. Congrats on the quarter. My question ties back to an earlier question. And it has to do with sequential growth in Q2. I know, the question was framed around the IDF seasonality, but we do have kind of one month down here in Q2. And I'm just – one month completed here in Q2. And I'm just wondering, if you saw anything there that would lead you to believe that your normal seasonal pattern of Q2 being greater than Q1 on the revenue side. Is there anything that you see disrupting that?

We don't right now, Eric. We – yeah as we said that, seasonality should be consistent through the year at least for the next couple of quarters.

Okay. And then I wanted to talk about, the reloading pattern of the brands that you're working with. And by that, I mean, they come in with an insertion order they come in with an RFP that reloading process, I guess that you're having good win rates on the business that you're competing for. But are they coming back maybe with more deals that are smaller in size, because they don't know what the heck's in front of them? Or is it more deals of kind of similar or a larger size?

Steve, do you want to cover that? Yes.

Sure. The answer is both Eric. We're seeing more customers coming back so much higher renewal rate between periods, largely proven out I think by the return on investment that they're seeing from initial investments being made, either later last year or earlier this year which has been good. So volume up and also value is a key focus as well. And I think they're willing to spend more dollars as we've sort of discussed on the ACV piece with some of the enterprise yields that we're seeing.

Okay. I like the sound of that just because obviously you're selling to existing customers and it's bigger deals to those existing customers and a shorter deal cycles. It all sounds good to me. I have a question for Doug and this is off the cash flow statement. A pretty substantial paid expenses and other assets. I want to say about $2.1 million of prepaid expense another off a cash flow statement. Can you give us some color there?

Sure. That was related to a payment to one of our channel partners. It's kind of prepaid some of our costs for the year that should even out and come back to us over the course of the year.

Okay. And then obviously my next question is about -- you talked about getting to cash flow positive here. So I'm assuming, we don't have this kind of thing coming at us every quarter?

Sorry, you're a little faint. That should be coming back over the course of the whole year not all in the second quarter.

Okay. I think I've got my answers. Thanks for taking the question. Good luck.

Thanks, Eric.

And our next question comes from Alex Silverman with AWM Investments. Please go ahead. Can you push your mute function?

Sorry I missed that. Pardon me. Congratulations on a great quarter guys. My question is a little bit along the lines of Eric's though slightly different. As your clients think about their budgets and are aggressively spending in this period where their sales force is locked down, are they expanding budget digital budget? Are they moving budget dollars around? Are they onetime topping off? How are they thinking about this?

Alex, good to hear your voice. It's a mixed bag. And we deal with a lot of them. They're all handling it a little differently. But you can be sure that it's going to be ranked first by impact of revenue and those things that could be disrupted and not disrupted by engagement. So we're seeing some just increasing from shifting dollars. We're seeing others keep it where it is. And then we're seeing new brands come in that maybe weren't thinking of this channel or this strategy for right now and now they're reassessing. So it's a mix bag. Steve if you want to add go ahead.

No. I think you summed it up really well Will. What we haven't seen in the marketplace yet, Alex our significant layoff on sales or medical science liaisons from the manufacturers. We've seen them benched as we described earlier, but not pivoting dollars from headcount there into digital engagements. So it represents growth in spend.

Got it. Great. Thank you very much. The rest of my questions have all been asked and answered. Thanks again.

Thanks a lot.

At this time, this concludes our question-and-answer session. I'd now like to turn the call back over to Mr. Febbo. Please go ahead sir.

Thank you. Well if you can take just one thing away from our discussion today, I hope that's the understanding of our potential for strong growth and ability to generate lots of value for shareholders because of our sustainable strategic advantage. And beyond the numbers I hope you can see that we've created a unique corporate culture dedicated to something truly valuable, and which makes a difference in people's lives from patients to physicians and beyond. We don't give guidance as an early-stage public company and especially in this current environment, but given everything you've heard and what I can see, we are very optimistic for 2020 and feel like we will exceed our internal goals given the heightened need for digital communication with providers and patients for our clients. I look forward to speaking with our investors in the upcoming virtual conferences with BofA, William Blair and RBC in May and June. But as always, feel free to reach out directly with any questions or concerns. Now with that, we'll wrap up the call, and I hope you all stay healthy and well and I look forward to actually seeing you again. Take care.

And before we conclude today's call, I would like to provide the company's safe harbor statement that includes important cautions regarding forward-looking statements made during today's call. Statements made by management during today's call may contain forward-looking statements within the definition of Section 27A in the Securities Act of 1933 as amended and Section 21E at the Securities Act of 1934 as amended. These forward-looking statements should not be used to make any investment decision. The words anticipate estimate, expect, possible and seeking and similar expressions identify forward-looking statements as they speak only to the date that statements were made. Such forward-looking statements in the call include statements regarding estimation of total addressable market size, market penetration, revenue growth, growth margin, operating expenses, profitability, cash flow, technology, investments growth opportunities, acquisitions, upcoming announcements, and the need to raise additional capital. They also include the management's expectations for the rest of the year and adoption of the company's digital health platform. The company undertakes no obligation to publicly update or revise any forward-looking statements whether because of new information, future events or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying further forward-looking statements. The risks and uncertainties, to which forward-looking statements are subject include but are not limited to the effect of government regulation, competition and other material risks. Risks and uncertainties to which forward-looking statements are subject to could affect business and financial results are included in the company's annual report on Form 10-K for the fiscal year ended December 31 2019. This form is available on the company's website and on the SEC website at sec.gov. Before we end today's conference, I would like to remind everyone that this call will be available for replay starting later this evening and running through May 25th. Please refer to today's press release for dial-in replay instructions available via the company's website at www.optimizerx.com. Thank you for joining us today. This concludes today's call. You may now disconnect.